<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00729001</url>
  </required_header>
  <id_info>
    <org_study_id>444563/005</org_study_id>
    <nct_id>NCT00729001</nct_id>
  </id_info>
  <brief_title>Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants.</brief_title>
  <official_title>Phase II, Double-blind, Randomized, Placebo-controlled Study of 2 Doses of GSK Biologicals' Live Attenuated Human Rotavirus Vaccine at Different Virus Concentrations (10 5.2 and 10 6.4 Ffu) in Healthy Infants Following a 0, 2 Month Schedule and Previously Uninfected With Human Rotavirus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a dose exploration study to assess the safety and immunogenicity of two doses of the
      candidate HRV vaccine at different virus concentrations in the target age group (infants
      approximately 2 months of age and previously uninfected with human rotavirus) and receiving
      concomitant administration of routine vaccinations. The study also aims at exploring the
      effect of unrestricted feeding on the immunogenicity of the vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects enrolled from Eastern United States and Eastern Canada will continue their
      participation in the pilot efficacy follow-up (pilot efficacy subset).

      The third dose of IPV vaccine (IPOL) may be given at visit 3, 4 or another time, at the
      investigator's discretion.

      Comvax may be given in place of OmniHIB/ActHIB at Visit 1 and Visit 2 and the third dose of
      Comvax administered according to the prescribing information.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2000</start_date>
  <completion_date type="Actual">September 2002</completion_date>
  <primary_completion_date type="Actual">September 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with vaccine take</measure>
    <time_frame>Two months after the second dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of any grade 2 or 3 fever, vomiting or diarrhea</measure>
    <time_frame>Within the 15-day solicited follow-up period after any dose of study vaccine.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of each type of solicited symptoms</measure>
    <time_frame>Within the 15-day solicited follow-up period after any dose of study vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of unsolicited symptoms according to WHO classification.</measure>
    <time_frame>Within 42 days after dose 1 and dose 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of serious adverse events</measure>
    <time_frame>Throughout the entire study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum rotavirus immunoglobulin A (IgA) antibody titers</measure>
    <time_frame>At visits 1, 3 and 4 and at all Visits for pilot efficacy subset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rotavirus seropositivity status</measure>
    <time_frame>Before dose 1 and at the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine take (for pilot efficacy subset only)</measure>
    <time_frame>2 months after dose 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti- polyribosyl-ribitol phosphate (PRP), anti-diphtheria and anti-tetanus toxoids, anti- pertussis toxoid (PT), anti- filamentous haemagglutinin (FHA), anti- pertactin (PRN), anti-polio type 1, 2 and 3 antibody concentrations</measure>
    <time_frame>Two months after dose 2 and at the end of the study.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody concentrations to pneumococcal serotypes 4, 6B, 9V, 14, 18C, 19F and 23F</measure>
    <time_frame>Two months after dose 2 and at the end of the study (only in a subset of U.S. subjects)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PRP, anti-diphtheria, anti-tetanus, anti-polio type 1, 2 and 3 seroprotection status.</measure>
    <time_frame>Two months after dose 2 and at the end of the study.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PT, anti-FHA, anti-PRN, pneumococcal serotypes 4, 6B, 9V, 14, 18C, 19F and 23F (only in US subjects) seropositivity status.</measure>
    <time_frame>Two months after dose 2 and at the end of the study.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seropositivity status and Geometric mean titres (GMTs) of rotavirus IgA for breast fed infants compared with formula fed infants</measure>
    <time_frame>Two months after dose 2.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of rotavirus gastroenteritis (in a pilot efficacy subset of subjects)</measure>
    <time_frame>Two weeks after dose 2 until the end of the rotavirus season following vaccination.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">529</enrollment>
  <condition>Infections, Rotavirus</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human Rotavirus Vaccine - Formulation 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human Rotavirus Vaccine - Formulation 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Human Rotavirus Vaccine - two different formulations</intervention_name>
    <description>Two oral doses</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevnar</intervention_name>
    <description>Three-dose intramuscular injection (US subjects only)</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IPOL</intervention_name>
    <description>Two-dose intramuscular injection (US subjects only)</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix</intervention_name>
    <description>Three-dose intramuscular injection (US subjects only)</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OmniHIB</intervention_name>
    <description>Three-dose intramuscular injection (US subjects only)</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <other_name>ActHIB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pentacel</intervention_name>
    <description>Three-dose intramuscular injection (Canada only)</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male or female child between, and including 6 and 12 weeks (42-90 days) of age at
             the time of the first vaccination.

          -  Free of obvious health problems as established by medical history and clinical
             examination before entering into the study.

          -  Written informed consent obtained from the parents or guardians of the subject.

          -  Born after a normal gestation period (between 36 and 42 weeks).

        Exclusion Criteria:

          -  Use of any investigational or non-registered drug or vaccine other than the study
             vaccine within 30 days preceding the study vaccine or placebo or planned use during
             the study period.

          -  Planned administration of a vaccine (including routine pediatric vaccines) not
             foreseen by the study protocol during the period starting from 14 days before each
             dose of vaccine(s) and ending 14 days after. Hepatitis B vaccine given concomitantly
             or within 14 days before and after vaccination is not an exclusion criteria.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs since birth.

          -  History of diphtheria, tetanus, pertussis, polio, Hib disease and/or invasive
             pneumococcal infection. History of invasive pneumococcal infection is not an exclusion
             criteria for Canadian subjects.

          -  Previous vaccination against diphtheria, tetanus, pertussis, polio, Haemophilus
             influenzae type b, and/or Streptococcus pneumoniae. Previous vaccination against
             Streptococcus pneumoniae is not an exclusion criteria for Canadian subjects.

          -  Use of antibiotics within 7 days preceding dose 1.

          -  Any clinically significant history of chronic gastrointestinal disease including any
             uncorrected congenital malformation of the GI tract or other serious medical condition
             as determined by the investigator.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including
             human immunodeficiency virus (HIV) infection.

          -  History of allergic disease or reaction likely to be exacerbated by any component of
             the vaccine.

          -  Acute disease at time of enrollment.

          -  Gastroenteritis within 7 days preceding the study vaccine administration.

          -  Household contact with an immunosuppressed individual or pregnant women.

          -  Administration of immunoglobulins and/or blood products since birth or planned
             administration during the study period.

          -  Previous confirmed occurrence of rotavirus gastroenteritis.

          -  Inability to contact parents/guardians of the subject by telephone.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Dennehy PH; North American Human Rotavirus Vaccine Study Group. A short report on the highlights of world-wide development of RIX4414: a North American experience comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine (RIX4414) in infants in the United States and Canada. Vaccine. 2006 May 1;24(18):3780-1. Epub 2005 Aug 1.</citation>
    <PMID>16111790</PMID>
  </reference>
  <reference>
    <citation>Dennehy PH, Brady RC, Halperin SA, Ward RL, Alvey JC, Fischer FH Jr, Innis BL, Rathfon H, Schuind A, De Vos B; North American Human Rotavirus Vaccine Study Group. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. Pediatr Infect Dis J. 2005 Jun;24(6):481-8.</citation>
    <PMID>15933555</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2008</study_first_submitted>
  <study_first_submitted_qc>August 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2008</study_first_posted>
  <last_update_submitted>September 15, 2016</last_update_submitted>
  <last_update_submitted_qc>September 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rotavirus Gastroenteritis</keyword>
  <keyword>Human rotavirus vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rotavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>444563/005</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>444563/005</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>444563/005</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>444563/005</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>444563/005</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>444563/005</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

